Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

Combining Immune Therapy, Pembrolizumab, and Chemotherapy as First Line Treatment for Lung Cancer

Research Question:
Is treatment with one chemotherapy medication combined with immune therapy (pembrolizumab) tolerable and effective for patients with lung cancer?

Basic Study Information

Purpose:
The purpose of this study is to understand if treatment with one chemotherapy medication combined with immune therapy (pembrolizumab) is tolerable and effective for patients with lung cancer and performance status of 2 (PS2), which means you have limitations in carrying out certain activities or spend up to half of your day resting.

Location: University of Rochester Medical Center
Study Reference #: ULUN19148

Lead Researcher (Principal Investigator)

Lead Researcher:  Megan Baumgart

Study Contact Information

Study Coordinator: Amy Jasek
Phone: (585) 273-1912
Email: Amy_Jasek@URMC.Rochester.edu

Additional Study Details

Return to Search